{"symbol":"REGN","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2026","preBrief":{"companySnapshot":"Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines for serious diseases. As a key player in the health care sector, Regeneron is known for its innovative treatments and research in areas like eye diseases, cancer, and inflammatory conditions.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth is essential to assess the company's ability to expand its market presence and drive future profits.","consensus":"N/A"},{"name":"Product Pipeline Updates","why":"Updates on the product pipeline can provide insights into future revenue streams and the company's growth potential.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Regeneron reported an impressive EPS of $9.47, significantly beating estimates by over 50%. However, the stock reacted negatively, dropping 6.21% the following day.","promises":["Focus on expanding the product pipeline.","Commitment to maintaining strong financial performance.","Plans to enhance research and development efforts."]},"wallStreetExpectations":{"summary":"Overall, expectations are mixed heading into the earnings report, with investors looking for continued strong performance but wary of potential market volatility.","bullCase":"If Regeneron continues its trend of beating EPS estimates, it could signal robust growth and innovation, leading to a positive stock reaction.","bearCase":"Conversely, any signs of slowing revenue growth or issues in the product pipeline could lead to a negative market reaction."},"optionsSignal":{"impliedMove":"13.18%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+50.70%","reaction":"-6.21%"},{"quarter":"Q4-2025","epsSurprise":"+38.18%","reaction":"-1.07%"},{"quarter":"Q3-2025","epsSurprise":"+57.31%","reaction":"+11.82%"},{"quarter":"Q2-2025","epsSurprise":"+94.45%","reaction":"+2.46%"},{"quarter":"Q1-2025","epsSurprise":"+24.32%","reaction":"-6.87%"}],"pivotalQuestions":[{"question":"What is the expected EPS for this quarter?","whyItMatters":"Given the company's history of beating EPS estimates, this number will be crucial for determining market sentiment."},{"question":"What updates can be provided on the product pipeline?","whyItMatters":"Insights into the product pipeline will help investors gauge future growth potential and revenue streams."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $10.00 or higher would confirm strong financial health and growth potential.","bearTrigger":"An EPS below $8.00 could indicate underlying issues and lead to a negative market reaction.","context":"The market is debating whether Regeneron can sustain its impressive growth trajectory amid increasing competition and market pressures."},"scenarioPlaybook":{"beatAndRaise":"If Regeneron beats expectations, history suggests the stock could see an average one-day move of +11.82%, confirming strong growth.","inLineCautious":"If results are in line with expectations, the stock may react modestly, reflecting cautious sentiment among investors.","miss":"A miss could lead to a decline, with history suggesting an average one-day move of -6.87%, indicating investor disappointment."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Regeneron's ability to continue its strong EPS performance, given its historical track record of beating estimates.","supportingPoints":["Regeneron has consistently exceeded EPS expectations in the past quarters.","Options pricing suggests a larger move than historical averages, indicating potential for a significant surprise.","Insider buying activity may signal confidence in the company's future performance."],"riskToConsensus":"If EPS comes in below $8.00, it could undermine the bullish sentiment."},"whatToListenFor":["Any updates on the product pipeline and expected launch dates.","Management's outlook on revenue growth for the upcoming quarters.","Details on any new partnerships or collaborations.","Insights into cost management strategies and their impact on margins.","Any commentary on competitive pressures in the biotechnology space."],"metaDescription":"Regeneron Pharmaceuticals (REGN) reports Q2 2026 earnings July 30. Investors are watching for EPS and product pipeline updates."}}